These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 16391722)

  • 1. Molecule of the month. Bifeprunox mesilate.
    Drug News Perspect; 2005 Oct; 18(8):523. PubMed ID: 16391722
    [No Abstract]   [Full Text] [Related]  

  • 2. DU-127090 Solvay/H Lundbeck.
    Wolf W
    Curr Opin Investig Drugs; 2003 Jan; 4(1):72-6. PubMed ID: 12625033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.
    Newman-Tancredi A; Cussac D; Depoortere R
    Curr Opin Investig Drugs; 2007 Jul; 8(7):539-54. PubMed ID: 17659474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bifeprunox vs Placebo for Schizophrenia.
    Chattopadhyay A; Frey S; Green G; Harkness A; McDermott A; Yates A
    Schizophr Bull; 2016 Jul; 42(4):881-2. PubMed ID: 27153863
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecule of the month. Paliperidone.
    Drug News Perspect; 2007 Jun; 20(5):333. PubMed ID: 17878961
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory science in Europe: the case of schizophrenia trials.
    Barbui C; Bighelli I
    Lancet; 2013 Oct; 382(9900):1234-5. PubMed ID: 23791471
    [No Abstract]   [Full Text] [Related]  

  • 7. The Clinical Antipsychotic Trials of Intervention Effectiveness: what did we learn?
    Boyd MA
    Arch Psychiatr Nurs; 2008 Feb; 22(1):56-8. PubMed ID: 18207059
    [No Abstract]   [Full Text] [Related]  

  • 8. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.
    Fraley ME
    Expert Opin Ther Pat; 2009 Sep; 19(9):1259-75. PubMed ID: 19552508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpreting the results of the CATIE study.
    Luchins DJ
    Psychiatr Serv; 2006 Jan; 57(1):139-40. PubMed ID: 16399979
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():3-4. PubMed ID: 17286521
    [No Abstract]   [Full Text] [Related]  

  • 11. Schizophrenia drug says goodbye to dopamine.
    Weinberger DR
    Nat Med; 2007 Sep; 13(9):1018-9. PubMed ID: 17828217
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study.
    Montejo AL; Rico-Villademoros F;
    J Clin Psychopharmacol; 2008 Oct; 28(5):568-70. PubMed ID: 18794656
    [No Abstract]   [Full Text] [Related]  

  • 13. Antipsychotic medication adherence in schizophrenia.
    Byerly MJ; Nakonezny PA; Lescouflair E
    Psychiatr Clin North Am; 2007 Sep; 30(3):437-52. PubMed ID: 17720031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 15. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
    Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
    Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.
    Stroup TS; Alves WM; Hamer RM; Lieberman JA
    Nat Rev Drug Discov; 2006 Feb; 5(2):133-46. PubMed ID: 16518380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia.
    Citrome L
    Int J Clin Pract; 2008 May; 62(5):837-40. PubMed ID: 18412940
    [No Abstract]   [Full Text] [Related]  

  • 19. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    Citrome L; Stroup TS
    Int J Clin Pract; 2006 Aug; 60(8):933-40. PubMed ID: 16893436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone (Invega) for schizophrenia.
    Med Lett Drugs Ther; 2007 Mar; 49(1256):21-3. PubMed ID: 17351558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.